REVIEW OF REIMBURSEMENT DECISION DRIVERS FOR RARE CANCER THERAPIES ACROSS EU5 MARKETS

被引：0
|
作者：
Gupta, J. [1 ]
Wahal, V. P. [2 ]
机构：
[1] DRG Abacus, Gurgaon, India
[2] DRG Market Access Insights, Gurgaon, India
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.965
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY138
引用
收藏
页码：A569 / A569
页数：1
相关论文
共 50 条
  • [1] REVIEW OF RARE DISEASE REGISTRIES ACROSS EU5 COUNTRIES
    Gupta, P.
    Kumar, J.
    Gupta, J.
    VALUE IN HEALTH, 2017, 20 (09) : A571 - A571
  • [2] THE PROMISING FUTURE OF DIGITAL HEALTH: A ROAD TO REIMBURSEMENT IN US & EU5 MARKETS?
    Sheppard, H.
    VALUE IN HEALTH, 2023, 26 (12) : S432 - S432
  • [3] TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5
    Prada, M.
    Berard, I
    Walzer, S.
    Darba, J.
    Greenwood, B.
    VALUE IN HEALTH, 2018, 21 : S264 - S264
  • [4] TIME TO REIMBURSEMENT FOR ONCOLOGY DRUGS IN EU5
    Prada, M.
    Berard, I
    Walzer, S.
    Darba, J.
    Greenwood, B.
    VALUE IN HEALTH, 2018, 21 : S47 - S47
  • [5] INPATIENT POLICIES AND REQUIREMENTS FOR THE REIMBURSEMENT OF NOVEL THERAPIES OUTSIDE THE DRG IN THE US AND EU5
    Shah, S.
    Koka, N. S.
    Patel, K.
    Ahmad, M.
    Nair, S.
    Syed, A. A.
    Malempati, Y.
    VALUE IN HEALTH, 2023, 26 (06) : S228 - S228
  • [6] COMBINATION ONCOLOGY THERAPIES IN THE EU5: NAVIGATING THE ROAD TO REIMBURSEMENT AND OPTIMIZING UPTAKE IN MALIGNANT MELANOMA
    Privolnev, Y.
    Cox, J.
    Webster, R.
    VALUE IN HEALTH, 2018, 21 : S54 - S54
  • [7] ACCESS AND REIMBURSEMENT FOR CURRENT AND EMERGING ALZHEIMER'S DISEASE-MODIFYING THERAPIES IN THE EU5
    Privolnev, Y.
    Blutstein, T.
    Cox, J.
    Reyes, A.
    VALUE IN HEALTH, 2018, 21 : S344 - S344
  • [8] TIME TO REIMBURSEMENT FOR ORPHAN DRUGS IN EU5 IN THE LAST FIVE YEARS
    Molchanova, E.
    Benazet, F.
    Vollmer, L.
    Pomares, E.
    Danev, V
    Prada, M.
    VALUE IN HEALTH, 2020, 23 : S701 - S701
  • [9] DIFFERENCE BETWEEN UNITED STATES AND EU AUTHORISATION TIMELINES AND TIME TO REIMBURSEMENT IN THE EU5
    Sun, D.
    Beckerman, R.
    VALUE IN HEALTH, 2014, 17 (03) : A17 - A17
  • [10] TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5 IN THE LAST THREE YEARS
    Prada, M.
    Benazet, F.
    Berard, I
    Vollmer, L.
    Cuesta, M.
    Guterres, S.
    VALUE IN HEALTH, 2019, 22 : S854 - S854
12345